Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8<sup>+</sup> T cell responses.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35233545.
- Also identified by DOI 10.1016/j.xcrm.2022.100520 and PMC identifier 8768424.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19) pandemic. Currently developed vaccines inducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-antigen-specific neutralizing antibodies (NAbs) are effective, but the appearance of NAb-resistant S variant viruses is of great concern. A vaccine inducing S-independent or NAb-independent SARS-CoV-2 control may contribute to containment of these variants. Here, we investigate the efficacy of an intranasal vaccine expressing viral non-S antigens against intranasal SARS-CoV-2 challenge in cynomolgus macaques. Seven vaccinated macaques exhibit significantly reduced viral load in nasopharyngeal swabs on day 2 post-challenge compared with nine unvaccinated controls. The viral control in the absence of SARS-CoV-2-specific NAbs is significantly correlated with vaccine-induced, viral-antigen-specific CD8<sup>+</sup> T cell responses. Our results indicate that CD8<sup>+</sup> T cell induction by intranasal vaccination can result in NAb-independent control of SARS-CoV-2 infection, highlighting a potential of vaccine-induced CD8<sup>+</sup> T cell responses to contribute to COVID-19 containment.
Medical subject headings
- Administration, Intranasal
- Antibodies, Neutralizing
- Antibodies, Viral
- CD8-Positive T-Lymphocytes
- COVID-19
- COVID-19 Vaccines
- SARS-CoV-2
- Vaccination